DENVER and CHICAGO, October 11, 2021 – It is with deep sadness that TriSalus Life Sciences® today announced the unexpected passing of Alan Mendelson, a member of the company’s Board of Directors, over this past weekend.
“On behalf of our Board of Directors and employees, we extend our sincere condolences to Alan’s family and loved ones,” said Mary Szela, chief executive officer and president of TriSalus Life Sciences.
“Alan was a biotech luminary with a legacy of incredible business and legal acumen, strategy and company building skills. He was truly a leader who inspired and taught us all with his inquisitive nature and creative thinking. We will miss his passion for business excellence, wise counsel and invaluable friendship,” Szela continued.
Mr. Mendelson was appointed as a director of TriSalus in July 2021 after retiring as a senior partner in Latham & Watkins LLP. Over nearly 50 years of practice, he represented emerging and public growth companies, primarily in the life sciences industry, and served as global co-chair of the firm’s Life Sciences Industry Group. As its incorporator in 1980, Mendelson played a leading role in Amgen’s first decade, and previously served as the company’s secretary and acting general counsel.
Lending significant expertise to various boards throughout his lifetime, his previous positions included the Board of Trustees of the UC Berkeley Foundation, the Board of Trustees of the Buck Institute for Research on Aging, and the Board of Directors of the National Kidney Foundation, along with public and private biotechnology and life sciences companies.
Throughout his career, Mr. Mendelson was recognized for his contributions and commitment to the life sciences industry. He was a recipient of a Life Sciences Leadership Award at the BayBio Pantheon, and one of only four individuals to have a star in Legal 500’s Hall of Fame for legal professionals serving the life sciences sector.
About TriSalus Life Sciences
TriSalus Life Sciences is an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated. TriSalus’ organ-specific platform integrates therapeutics and innovative device technology to address the dual challenges of immunosuppression and pressure, two of the most significant barriers that limit the effectiveness of current treatments in liver and pancreatic cancer.
The company’s lead investigational compound, SD-101, aims to reactivate the immune system within these organs to fight cancer and enhance the effectiveness of other immunotherapy cancer treatments designed to limit cancer growth (e.g., checkpoint inhibitors, CAR T-cell therapy). The device, which leverages TriSalus’ FDA-cleared, Pressure-Enabled Drug Delivery™ (PEDD™) technology, is intended to open up collapsed blood vessels, overcoming pressure inside the tumor to deliver medicine deep inside. While meaningful progress in these difficult-to-treat diseases will not be easy, TriSalus is seeking to transform the battle with liver and pancreatic cancer through deep science, technology innovation, and an absolute focus on the patient. To learn more, visit us at www.trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn.